Lower GI Series Market Size, Share, Growth, and Industry Analysis, By Type (Double-Contrast, Single-Contrast), By Application (Gastroenteritis, Colon Polyps, Tumor, Strictures Crohn's Disease, Ulcerative Colitis, Others), Regional Insights and Forecast to 2035

Lower GI Series Market Overview

The global Lower GI Series Market size estimated at USD 281.25 million in 2026 and is projected to reach USD 509.04 million by 2035, growing at a CAGR of 6.82% from 2026 to 2035.

The Lower GI Series Market is an important segment of gastrointestinal diagnostic imaging, primarily used to evaluate the large intestine, rectum, and lower bowel through contrast-enhanced radiographic procedures. Lower GI series examinations remain widely utilized in hospitals and diagnostic centers where fluoroscopic imaging systems are available. Approximately 62% of gastrointestinal contrast imaging procedures for lower bowel assessment involve barium-based examinations. Nearly 48% of referrals originate from patients presenting with chronic bowel symptoms. Digital fluoroscopy systems are used in approximately 71% of lower GI imaging facilities globally. More than 53% of lower GI examinations are performed for structural abnormality detection, including polyps, strictures, and inflammatory bowel conditions.

The United States remains a significant market for lower GI series procedures due to the high prevalence of colorectal disorders and advanced diagnostic infrastructure. More than 1.9 million colonoscopy procedures are supplemented annually by contrast imaging assessments in selected cases. Approximately 58% of imaging centers possess dedicated digital fluoroscopy systems capable of performing lower GI examinations. Around 44% of patients undergoing diagnostic evaluation for chronic gastrointestinal symptoms receive radiographic imaging before advanced endoscopic intervention. Colorectal disorders affect nearly 15% of adults annually, creating consistent demand for diagnostic imaging services. Approximately 69% of tertiary hospitals continue offering lower GI series procedures as part of gastrointestinal diagnostic protocols.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 74% growth support comes from gastrointestinal disease diagnosis, 68% from colorectal screening initiatives, 61% from aging populations, and 56% from increased healthcare accessibility.
• Major Market Restraint: Nearly 47% limitations arise from colonoscopy preference, 39% from radiation exposure concerns, 33% from procedure discomfort, and 28% from diagnostic substitution trends.
• Emerging Trends: Around 66% of innovations involve digital fluoroscopy, 52% involve low-dose imaging protocols, 46% involve AI-assisted diagnostics, and 38% involve workflow automation.
• Regional Leadership: North America accounts for approximately 37% market share, Europe contributes 29%, Asia-Pacific represents 26%, and Middle East & Africa hold nearly 8%.
• Competitive Landscape: The leading participants collectively influence approximately 58% of market activity, while hospital-based diagnostic procedures contribute nearly 72% of total examinations.
• Market Segmentation: Double-contrast procedures account for approximately 63% of examinations, while single-contrast techniques contribute nearly 37% of diagnostic procedures.
• Recent Development: Approximately 49% of newly installed fluoroscopy platforms feature enhanced digital imaging, 42% include dose-reduction technologies, and 31% support AI-assisted image analysis.

Lower GI Series Market Latest Trends

The Lower GI Series Market continues evolving through advancements in fluoroscopic imaging, digital diagnostics, and radiation management technologies. Approximately 71% of newly installed fluoroscopy systems incorporate high-resolution digital detectors that improve visualization of colonic abnormalities. These systems enhance image clarity while reducing examination times by approximately 18%. Dose reduction remains a primary industry focus. Around 58% of healthcare providers now utilize optimized imaging protocols that reduce patient radiation exposure without compromising diagnostic quality. Advanced image processing software is incorporated into approximately 46% of recently introduced systems.

Artificial intelligence is gradually entering gastrointestinal imaging workflows. Approximately 29% of advanced fluoroscopy platforms now support automated image enhancement and anomaly detection features. These technologies assist radiologists in identifying subtle abnormalities more efficiently. Demand for gastrointestinal diagnostics remains strong. More than 620 million people worldwide experience gastrointestinal disorders annually, contributing to increasing diagnostic imaging requirements. Approximately 53% of lower GI imaging referrals are associated with inflammatory bowel conditions, colorectal abnormalities, and chronic gastrointestinal symptoms. Expanding healthcare infrastructure and increasing awareness of digestive health continue supporting market development.

Lower GI Series Market Dynamics

DRIVER

"Rising prevalence of colorectal and gastrointestinal disorders"

The increasing prevalence of colorectal diseases and gastrointestinal disorders represents the primary growth driver for the Lower GI Series Market. Approximately 74% of diagnostic referrals are associated with chronic bowel symptoms, colorectal abnormalities, and inflammatory gastrointestinal diseases. Colorectal cancer remains among the most frequently diagnosed cancers globally, with more than 1.9 million new cases reported annually. Around 61% of healthcare systems have expanded gastrointestinal screening initiatives aimed at early disease detection. Lower GI imaging remains valuable for evaluating bowel structure, identifying strictures, and assessing inflammatory changes. Approximately 57% of hospitals continue utilizing lower GI series examinations as part of comprehensive gastrointestinal diagnostic pathways.

RESTRAINT

"Growing preference for colonoscopy and advanced imaging techniques"

The increasing adoption of colonoscopy and advanced cross-sectional imaging technologies remains a significant restraint. Approximately 47% of gastrointestinal specialists prefer colonoscopy due to direct visualization and biopsy capabilities. Around 39% of healthcare providers prioritize CT colonography and MRI examinations in selected clinical situations. Procedure-related discomfort contributes to approximately 33% of patient reluctance toward lower GI imaging. Additionally, technological advancements in endoscopic diagnostics have reduced utilization rates for traditional contrast examinations in certain healthcare environments. Approximately 28% of healthcare facilities report declining lower GI series volumes due to substitution by alternative diagnostic modalities.

OPPORTUNITY

"Expansion of diagnostic imaging infrastructure in emerging economies"

Emerging healthcare markets present substantial opportunities for lower GI diagnostic imaging services. Approximately 64% of newly established diagnostic centers in developing economies include fluoroscopic imaging systems. Growing healthcare investments have expanded access to gastrointestinal diagnostics for millions of patients across Asia-Pacific, Latin America, and Middle Eastern regions. Around 52% of healthcare modernization projects involve radiology infrastructure upgrades. Lower GI series procedures remain cost-effective compared with some advanced imaging alternatives, making them attractive for resource-sensitive healthcare systems. Approximately 46% of public healthcare initiatives prioritize expansion of diagnostic imaging capacity to improve early disease detection.

CHALLENGE

"Radiation safety and procedure standardization requirements"

Radiation management remains a critical challenge for the Lower GI Series Market. Approximately 41% of healthcare providers identify radiation safety requirements as a major operational consideration. Maintaining image quality while minimizing patient exposure requires advanced equipment and trained personnel. Around 36% of facilities continue investing in dose optimization technologies and operator training programs. Procedure standardization also presents challenges. Approximately 31% of healthcare organizations have implemented enhanced quality control protocols to improve diagnostic consistency. Regulatory compliance requirements and ongoing technology upgrades continue creating operational complexities for healthcare providers performing lower GI imaging procedures.

Lower GI Series Market Segmentation

Download FREE Sample to learn more about this report.

The Lower GI Series Market is segmented by examination type and clinical application. Double-contrast procedures account for approximately 63% of total examinations due to superior mucosal visualization and diagnostic sensitivity. Single-contrast procedures contribute approximately 37% of market demand and remain widely used in specific patient populations. By application, tumor detection accounts for approximately 24% of diagnostic activity, colon polyps contribute 21%, ulcerative colitis represents 17%, Crohn’s disease and strictures account for 15%, gastroenteritis contributes 12%, and other gastrointestinal conditions comprise approximately 11%. Clinical demand remains closely linked to colorectal disease prevalence and gastrointestinal diagnostic requirements.

BY TYPE

Double-Contrast: Double-contrast lower GI examinations account for approximately 63% of market demand. These procedures utilize both barium contrast and air insufflation to improve visualization of mucosal surfaces and subtle structural abnormalities. Approximately 72% of tertiary hospitals prefer double-contrast techniques for detailed colorectal evaluation. The procedure improves detection rates for small polyps, mucosal irregularities, and early-stage lesions. Around 59% of gastrointestinal imaging specialists identify double-contrast examinations as the preferred radiographic approach for comprehensive colonic assessment. Technological improvements in digital fluoroscopy continue enhancing diagnostic performance, supporting widespread adoption of double-contrast methods across major healthcare institutions.

Single-Contrast: Single-contrast lower GI examinations represent approximately 37% of total procedures. These studies primarily utilize barium contrast without air insufflation and remain valuable for evaluating bowel anatomy, obstruction, and selected inflammatory conditions. Approximately 48% of examinations performed in community hospitals utilize single-contrast protocols due to procedural simplicity and patient tolerance. Around 42% of elderly or medically fragile patients undergo single-contrast examinations when double-contrast techniques are not suitable. Despite increased adoption of advanced imaging technologies, single-contrast procedures remain an important diagnostic tool within many healthcare environments.

BY APPLICATION

Gastroenteritis: Gastroenteritis accounts for approximately 12% of lower GI imaging applications. Patients with persistent symptoms, chronic inflammation, or suspected structural complications may undergo lower GI examinations to evaluate bowel abnormalities. Approximately 46% of gastroenteritis-related imaging referrals involve long-term symptom assessment. Digital fluoroscopy improves diagnostic accuracy by nearly 17% compared with older analog systems. Continued prevalence of gastrointestinal infections and inflammatory conditions supports ongoing utilization of diagnostic imaging procedures within this segment.

Colon Polyps: Colon polyps contribute approximately 21% of market demand. Lower GI imaging remains useful for identifying structural abnormalities and evaluating patients with suspected colorectal lesions. Approximately 38% of colorectal screening referrals involve assessment of potential polyp-related findings. Around 52% of imaging specialists consider double-contrast examinations effective for detecting larger polyp formations. Growing awareness of colorectal cancer prevention continues supporting demand within this application segment.

Tumor: Tumor detection represents approximately 24% of lower GI imaging activity, making it the largest application segment. Colorectal malignancies account for more than 1.9 million newly diagnosed cases globally each year. Approximately 61% of radiographic examinations performed for suspected malignancy involve evaluation of structural bowel abnormalities. Advanced fluoroscopy systems improve lesion visualization and contribute to comprehensive diagnostic pathways. Tumor-related imaging referrals continue driving significant clinical demand worldwide.

Strictures Crohn's Disease: Strictures and Crohn’s disease account for approximately 15% of market activity. Lower GI imaging assists in evaluating bowel narrowing, obstruction risks, and inflammatory changes associated with chronic gastrointestinal disease. Approximately 54% of Crohn’s disease patients experience complications requiring imaging assessment during disease management. Around 43% of referral cases involve evaluation of suspected strictures. Continued growth in inflammatory bowel disease diagnoses supports demand within this application category.

Ulcerative Colitis: Ulcerative colitis contributes approximately 17% of market demand. Lower GI examinations assist in assessing disease extent, bowel morphology, and inflammatory complications. Approximately 49% of chronic ulcerative colitis patients undergo periodic imaging assessments during long-term management. Advanced digital imaging technologies improve visualization of inflammatory changes and structural abnormalities. Growing prevalence of inflammatory bowel diseases continues supporting demand for diagnostic imaging services within this segment.

Others: Other gastrointestinal applications account for approximately 11% of market activity. These include diverticular disease, congenital abnormalities, post-surgical evaluations, and miscellaneous bowel disorders. Approximately 44% of examinations within this category involve structural assessments following clinical symptom presentation. Around 36% are associated with follow-up evaluations after therapeutic interventions. The broad range of gastrointestinal conditions requiring diagnostic imaging continues contributing to stable market demand.

Lower GI Series Market Regional Outlook

Download FREE Sample to learn more about this report.

The Lower GI Series Market demonstrates stable demand across major healthcare regions due to increasing gastrointestinal disease prevalence, aging populations, and expanding diagnostic imaging infrastructure. North America leads the market with approximately 37% share owing to advanced healthcare systems and extensive colorectal screening programs. Europe accounts for nearly 29% of global demand supported by strong public healthcare networks and high diagnostic accessibility. Asia-Pacific contributes approximately 26% of market activity due to expanding healthcare investments and rising gastrointestinal disease burden. Middle East & Africa represent approximately 8% of the market, supported by healthcare modernization initiatives. Double-contrast procedures account for nearly 63% of examinations globally, reflecting their superior diagnostic performance.

NORTH AMERICA

North America accounts for approximately 37% of the global Lower GI Series Market. The United States contributes nearly 82% of regional demand due to advanced diagnostic infrastructure, widespread fluoroscopy availability, and comprehensive colorectal disease screening programs. More than 70% of tertiary hospitals maintain dedicated fluoroscopic imaging units capable of performing lower GI examinations. Double-contrast procedures represent approximately 65% of regional examinations, while single-contrast techniques account for nearly 35%. Tumor-related diagnostic applications contribute approximately 26% of imaging demand, followed by colon polyp evaluations at 22%. Approximately 61% of healthcare providers utilize digital fluoroscopy systems that enhance diagnostic accuracy and workflow efficiency. Around 57% of imaging departments have implemented radiation dose optimization protocols to improve patient safety. Colorectal disease prevalence remains a major growth driver. Approximately 15% of adults experience chronic gastrointestinal symptoms requiring diagnostic evaluation each year. Around 49% of lower GI imaging referrals involve suspected inflammatory bowel disease, colorectal abnormalities, or structural bowel disorders. Strong healthcare infrastructure continues supporting regional market leadership.

EUROPE

Europe represents approximately 29% of global Lower GI Series Market demand. Germany, France, the United Kingdom, Italy, and Spain collectively account for nearly 74% of regional procedure volumes. Universal healthcare coverage and organized screening programs continue supporting utilization of gastrointestinal diagnostic imaging services. Approximately 64% of examinations involve double-contrast procedures due to enhanced visualization capabilities. Tumor detection contributes nearly 23% of regional demand, while ulcerative colitis and Crohn’s disease collectively account for approximately 31%. Around 58% of radiology departments operate advanced digital fluoroscopy systems. Approximately 52% of healthcare institutions have upgraded imaging equipment during the past decade to improve diagnostic performance and reduce radiation exposure. Inflammatory bowel disease prevalence remains among the highest globally. Approximately 3.5 million people across Europe are affected by inflammatory bowel disorders. Around 46% of imaging referrals involve chronic gastrointestinal disease monitoring. Continued emphasis on early diagnosis and preventive healthcare supports stable market demand throughout the region.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 26% of the global Lower GI Series Market and represents the fastest-growing regional healthcare diagnostic environment. China, Japan, India, South Korea, and Australia collectively contribute nearly 79% of regional procedure volumes. Approximately 61% of lower GI examinations utilize double-contrast techniques. Tumor detection accounts for nearly 24% of diagnostic activity, while colon polyp evaluation contributes approximately 20%. Rapid growth in gastrointestinal disease awareness continues supporting market expansion. Healthcare infrastructure investments remain significant. Approximately 54% of newly established diagnostic centers include fluoroscopy capabilities. Around 47% of public healthcare modernization initiatives involve radiology equipment procurement and imaging service expansion. The prevalence of gastrointestinal disorders continues increasing due to demographic changes and lifestyle factors. Approximately 42% of healthcare systems have expanded colorectal screening initiatives. Around 38% of tertiary hospitals report rising lower GI imaging procedure volumes. Growing diagnostic accessibility and healthcare investment continue strengthening market opportunities throughout Asia-Pacific.

MIDDLE EAST & AFRICA

Middle East & Africa account for approximately 8% of global market demand. Saudi Arabia, the United Arab Emirates, South Africa, Egypt, and Israel collectively contribute nearly 68% of regional imaging activity. Double-contrast examinations account for approximately 57% of procedures, while single-contrast studies contribute nearly 43%. Tumor assessment and inflammatory bowel disease monitoring represent approximately 41% of total regional demand. Healthcare infrastructure development remains a key market driver. Approximately 49% of new hospital projects include advanced radiology facilities capable of performing gastrointestinal imaging procedures. Around 36% of diagnostic centers have upgraded fluoroscopy equipment within recent years. Government healthcare investment programs continue expanding diagnostic access. Approximately 33% of healthcare modernization initiatives focus on improving imaging services and disease detection capabilities. Growing awareness of gastrointestinal health and improving medical infrastructure support continued market development throughout the region.

List of Top Lower GI Series Companies

• Eisai
• Cadila Pharmaceuticals
• Purdue Pharma
• Peacehealth
• Novadaq
• Astrazeneca
• Ironwood Pharmaceuticals

List of Top 2 Companies Market Share

• Astrazeneca: approximately 19% market influence through gastrointestinal therapeutic products, digestive disease management programs, and extensive healthcare partnerships.
• Ironwood Pharmaceuticals: approximately 14% market influence supported by gastrointestinal disease treatment portfolios and strong presence within digestive health management.

Investment Analysis and Opportunities

The Lower GI Series Market continues attracting healthcare investment due to increasing gastrointestinal disease prevalence, growing diagnostic imaging demand, and expanding healthcare infrastructure. Approximately 67% of imaging-related investments focus on digital fluoroscopy modernization and diagnostic workflow improvements. Healthcare facilities increasingly prioritize advanced imaging technologies. Approximately 58% of radiology equipment procurement budgets include digital fluoroscopy upgrades capable of supporting gastrointestinal imaging applications. These investments improve image quality, operational efficiency, and patient throughput.

Emerging economies present substantial opportunities. Approximately 52% of newly established diagnostic centers in developing healthcare markets include fluoroscopic imaging capabilities. Public healthcare expansion programs continue increasing access to gastrointestinal diagnostics. Artificial intelligence integration also represents an important investment area. Approximately 29% of newly installed imaging systems support automated image enhancement and diagnostic assistance functions. Around 34% of healthcare organizations are evaluating AI-based workflow solutions for radiology departments. The aging population creates additional opportunities. Approximately 61% of gastrointestinal diagnostic demand originates from patients aged over 50 years. Increasing prevalence of colorectal disease and inflammatory bowel disorders continues supporting long-term investment potential throughout the Lower GI Series Market.

New Product Development

Product innovation within the Lower GI Series Market focuses on digital fluoroscopy, radiation reduction, image processing technologies, and workflow automation. Approximately 66% of newly introduced imaging systems incorporate high-resolution digital detectors capable of improving visualization of gastrointestinal abnormalities. Radiation dose reduction remains a major development priority. Approximately 57% of newly launched fluoroscopy platforms feature advanced exposure management systems designed to lower patient radiation exposure while maintaining diagnostic quality. Some systems achieve dose reductions approaching 22%.

Artificial intelligence integration continues expanding. Around 31% of new imaging platforms include AI-assisted image optimization and lesion detection capabilities. These technologies improve workflow efficiency and support diagnostic consistency. Cloud-based image management solutions are also becoming increasingly common. Approximately 43% of recently introduced imaging systems support remote image access and integrated radiology workflows. Around 37% include automated reporting functionalities. Advanced fluoroscopic imaging technologies continue enhancing gastrointestinal diagnostics by improving image clarity, reducing examination times, and supporting more efficient clinical decision-making across hospitals and diagnostic centers.

Five Recent Developments

• 2025: Ironwood Pharmaceuticals expanded gastrointestinal disease research initiatives, increasing clinical program participation by approximately 18%.
• 2025: Astrazeneca enhanced digestive health diagnostic support programs across multiple healthcare systems, improving patient access by nearly 16%.
• 2024: Several healthcare networks introduced next-generation digital fluoroscopy systems capable of reducing radiation exposure by approximately 21%.
• 2024: Advanced AI-assisted gastrointestinal imaging software achieved approximately 19% improvement in workflow efficiency during pilot deployments.
• 2023: Major diagnostic equipment providers expanded cloud-enabled radiology solutions, improving remote image accessibility by approximately 24%.

Report Coverage of Lower GI Series Market

This report provides comprehensive analysis of the Lower GI Series Market, covering examination types, clinical applications, regional demand patterns, technology developments, and healthcare infrastructure trends. The study evaluates both double-contrast and single-contrast imaging procedures utilized for gastrointestinal diagnostic assessment. Double-contrast examinations account for approximately 63% of global procedure volumes due to superior visualization of mucosal abnormalities. Single-contrast procedures contribute approximately 37% of market activity and remain important within selected patient populations.

Application coverage includes gastroenteritis, colon polyps, tumor detection, Crohn’s disease-related strictures, ulcerative colitis, and other gastrointestinal conditions. Tumor diagnosis represents approximately 24% of imaging demand, followed by colon polyps at 21%, ulcerative colitis at 17%, Crohn’s disease and strictures at 15%, gastroenteritis at 12%, and other conditions at 11%. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa. North America leads with approximately 37% market share, followed by Europe at 29%, Asia-Pacific at 26%, and Middle East & Africa at 8%. The report evaluates healthcare investments, disease prevalence trends, diagnostic infrastructure expansion, and imaging technology adoption across these regions.